Pharmaceuticals

Global Focal Segmental Glomerulosclerosis Drugs Market Size Projected to Reach $24.79 Billion During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Focal Segmental Glomerulosclerosis Drugs Market Over The Five-Year Period 2025–2029?

The focal segmental glomerulosclerosis drugs market has demonstrated significant expansion over recent years. It is anticipated to increase from $15.77 billion in 2024 to $17 billion in 2025, progressing at a compound annual growth rate (CAGR) of 7.8%. This historical growth can be ascribed to factors such as the rising incidence of the disease, an increasing need for new therapeutic options, heightened interest from the pharmaceutical industry, and enhanced government assistance.

The market for focal segmental glomerulosclerosis drugs is anticipated to experience substantial expansion over the coming years. This market is projected to reach $24.79 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.9%. Factors contributing to this growth during the forecast period include increased spending on research and development, escalating healthcare costs, heightened awareness and improved diagnosis, an expanding elderly population, and various government initiatives and financial support. Key trends anticipated during this period encompass innovations in drug discovery and development technology, an expanding array of clinical trials, enhanced reimbursement policies for focal segmental glomerulosclerosis drug treatments, and the growth of corporate research infrastructure.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp

What Are The Top Growth Drivers Impacting The Focal Segmental Glomerulosclerosis Drugs Market Outlook?

The increasing occurrence of kidney infections is projected to fuel the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market in the future. A kidney infection, also known as pyelonephritis, represents a serious form of urinary tract infection (UTI) impacting either one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, prescribed for kidney diseases, provide multiple advantages in addressing the condition and enhancing kidney function. These benefits include decreasing proteinuria, slowing down the advancement of kidney damage, and contributing to a better quality of life for patients with kidney ailments. For example, data from July 2022 by the Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, indicated that approximately 15%, equating to 37 million people in the US, suffered from kidney disease. In 2021, the prevalence rate for individuals aged 45–64 stood at 12%, while among those between 18 and 44, it was 6%. Consequently, the growing incidence of kidney infections is propelling the focal segmental glomerulosclerosis (FSGS) market.

How Is The Focal Segmental Glomerulosclerosis Drugs Market Segmented?

The focal segmental glomerulosclerosis drugs market covered in this report is segmented –

1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types

2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments

3) By Route of Administration: Oral, Parenteral

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Which Trends Are Impacting The Focal Segmental Glomerulosclerosis Drugs Market?

Major companies operating in the focal segmental glomerulosclerosis (FSGS) market are increasingly prioritizing product development and innovation to deliver reliable products to their customers and strengthen their market position. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched FILSPARI for focal segmental glomerulosclerosis (FSGS), which received approval from the Food and Drug Administration (FDA), a US-based federal agency. This medication is an oral treatment for IgA nephropathy (IgAN). It stands as the first and only non-immunosuppressive treatment designed to lower proteinuria in IgAN, a rare kidney disease. Additionally, FILSPARI has been granted orphan drug designation in the United States and Europe for its use in treating IgAN and focal segmental glomerulosclerosis (FSGS).

Which Major Firms Are Strengthening Their Position In The Focal Segmental Glomerulosclerosis Drugs Industry?

Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

What Are The Regional Market Dynamics Impacting The Focal Segmental Glomerulosclerosis Drugs Industry?

North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Focal Segmental Glomerulosclerosis Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12866&type=smp

Browse Through More Reports Similar to the Global Focal Segmental Glomerulosclerosis Drugs Market 2025, By The Business Research Company

Kidney Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Diabetic Kidney Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Kidney Transplant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795